We set out to determine the seroprevalence of hepatitis B and C among human immunodeficiency virus type-1 (HIV-1) infected individuals in North-
Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) are devastating disease agents that share common modes of transmission (Santiago-Munoz et al. 2005) , therefore HIV positive individuals are at risk of co-infection with HBV and HCV infections. With the advent of highly active antiretroviral therapy (HAART) regimens capable of dramatically prolonging the survival of HIV-infected patients, the impact of co-morbid infections such as HBV and HCV has come into focus (Petoumenos & Ringland 2005) . Co-infection with HBV or HCV increases the risk for hepatotoxicity of HAART and likelihood of onset of an AIDS-defining illness, compared with infection with HIV-1 alone (Greub 2000 , Feld et al. 2005 . Although the HIV co-infection with HBV and/or HCV has been recognized worldwide in individuals exposed to bloodborne diseases, limited data are available on the extent of co-infection and effect of these viruses on the immune system in developing countries. Nigeria belongs to the group of countries highly endemic for viral hepatitis (Odemuyiwa et al. 2001) . Few studies have been done on HIV, HBV, HCV separately in Nigeria but the knowledge about the interrelationship between these viruses and their effect on the immune system remains unclear. This study was therefore carried out to estimate the prevalence of HBV and/or HCV seropositivity in a cohort of people living with HIV/AIDS in North-Central Nigeria and to investigate the effect of these viruses on CD4 + lymphocytes in the HAART era in Nigeria.
One hundred and eighty plasma samples were randomly selected from confirmed HIV-1 positive samples stored at -24 o C in the Virology laboratory of Innovative Biotech (IBL), Keffi, Nasarawa State, Nigeria. These samples were collected between June and December 2005 from clients who assessed IBL services for voluntary HIV counseling and testing or for other health needs. Before each client was bled, informed consent was obtained in accordance with IBL and international regulations. These samples were labeled with a serialized IBL code number that could not be linked to individuals. As patients were bled, a fluorescence-activated cell sorter system (Becton Dickenson FACSCount, Canada) was used to enumerate absolute values for CD4 + cells for each sample according to manufacturers instructions. The second CD4 + counts of clients who returned after HAART were also enumerated. The double antibody sandwich Shantest TM -HBsAg ELISA (Shantha Biotech Limited -India) was used for the detection of HBsAg in plasma following manufacturers instructions and the microplates read at a wavelength of 450 nm using the ELISA reader (BIO-RAD 2100, version 6.1, US). Anti-HCV antibodies were detected in plasma using the Anti-HCV-EIA-Avicenna (Avicenna Medical Center, Russia) which is a third generation quantitative ELISA that uses recombinant proteins and synthetic peptides derived from core and structural regions of HCV to detect the pres-ence of anti-HCV in plasma samples. The test was carried out and interpreted according to manufacturer's instructions. Demographic data (age and gender) for participants were retrieved from coded clients' electronic registration records maintained at IBL. To compare the proportion of HIV positive individuals co-infected with HBV and/or HCV, the chi-square test was used at 95% confidence level. The analysis was done after recording the data in a Microsoft Excel worksheet on a Windows-98 platform.
Of the 180 samples, 83 were from males and 97 from females. The age range of the patients in this study was 20-64 years. The seroprevalence of HIV/hepatitis viruses and the distribution of disease burden are as follows: HIV only = 61.1%; HBV/HIV only = 20.6%, HCV/HIV only = 11.1%, and HIV/HBV/HCV = 7.2%. The gender distribution and ages of the infected individuals are as shown: 110 HIV only (57 males: 53 females; mean age = 32 and 20 years respectively); 37 HIV/HBV (21 males: 16 females; mean age = 29 and 25 years respectively); 20 HIV/HCV (13 males: 7 females; mean age = 37 and 30 years respectively); 13 HIV/HBV/HCV (7 males: 6 females; mean age = 43 and 31 years respectively). The HAART has transformed HIV/AIDS from a uniformly fatal illness into a manageable chronic infection and has been shown to be able to restore CD4 + cells in HIV infected patients (Rathbun et al. 2006 ). The gains of HAART could be compromised by coinfection with hepatitis viruses as they are known to have adverse effects on the prognosis of HIV and hepatitis infections (Feld et al. 2005) . Consequently, increased attention has to be paid on coinfection of hepatitis viruses and HIV especially in the developing countries like Nigeria where these groups of viruses are endemic. In this study, 20.6% of HIV infected individuals were coinfected with HBV. Our study correlates with a recent study in Jos (Uneke et al. 2005) , that recorded that 25.9% of HIV-infected individuals were HBsAg seropositive. This study therefore confirms the endemicity of HBV infection and increased infection in HIV infected individuals. This calls for the need to strengthen the HBV vaccination program in Nigeria which is known to be able to considerably reduce the incidence of HBV infections. The average CD4 + count values for this group was 377 cells/µl which is lower than that for HIV mono-infection recorded (mean = 478 cells/µl). The natural history of HBV is known to be complicated by HIV-co-infection but the effect of HBV on the outcome of patients infected with HIV-1 is controversial (Rockstroh 2006) . The reasons for the CD4 + decline is not clear but it is known that there is an imbalance in peripheral blood T-lymphocyte subsets and turbulence in cellular immunity in the patients with chronic hepatitis B (Tian et al. 2005) . Also, lamivudine resistant mutations in HBV treatment have adverse effects on treatment response in HIV infected individuals coinfected with HBV.
We also found an HCV seroprevalence rate of 11.1% in the group of HIV-1 infected individuals sampled. Previous studies in Nigeria had reported an overall HCV prevalence of 2.9% among blood donors in Rivers state of Nigeria (Kaote et al. 2005) . Agwale et al. (2004) , had recorded an HCV seroprevalence rate of 8.2% among HIV infected Nigerians. There is a clear indication of increased HCV infection in HIV infected individual in Nigeria. It is known that HIV/HCV coinfected individuals accelerate rapidly to end-stage liver disease, AIDS defining clinical event and death (Greub 2000 , Monga et al. 2001 ). Unfortunately at this time, no effective vaccine has been developed against HCV infection. We also report a case of a 35 years old female client coinfected with HIV and HCV who virologically failed therapy (CD4 + decline from 199 to 66) after four months on HAART. We also record that, the rate of increase in CD4 + cells post-HAART does not change in HIV and hepatitis coinfection but HCV appears to hinder virological response to therapy. Although there have been case reports of clearance of HCV viraemia after initiation of HAART (Ranieri et al. 2003) , majority of available data indicates that HAART results in net increase in HCV viraemia (Chung et al. 2002) . We have recorded that 7.2% of individual do have triple coinfection with HIV/HBV/ HCV. As far as we know, this is the first report of HIV, HBV, and HCV triple combination coinfections in the same individuals in Nigeria. The CD4 + values of these group was significantly poorer (mean = 107 cells/µl: AIDS defining) when compared with individuals who have HIV infection alone (mean = 478 cells/µl). Triple coinfected individuals are more likely to present with lower CD4 + counts and therefore reduced host immunity. Triple coinfection is therefore a growing problem in Nigeria and needs careful attention owing to its adverse effects on HIV treatment response.
We have demonstrated that co-infection of HIV and hepatitis viruses (HBV and/or HCV) is on the increase in Nigeria and appears to decrease the CD4 + counts of patients who are coinfected especially with triple coinfection of HIV, HBV, and HCV. Treatment of either hepatitis virus is complex because of pharmacokinetic interactions with components of HAART regimens. Thus, the phenomenon of HIV and hepatitis viruses coinfection is a cause for concern. The medical community in Nigeria therefore needs to be alert to this phenomenon as smart treatment options would need to be instituted in such individuals if treatment is to be meaningful.
